Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis

doi:10.12998/wjcc.v10.i19.6360

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4093)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series.

Item

Count

PDF

212

WORD

HTML

1877

Figures (1-5)

509

Sum=2658

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

219

Download

408

Sum=627

Publishing Process of This Article

Item

Count

Browse

296

Download

512

Sum=808

Jul 6, 2022 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. Jul 6, 2022; 10(19): 6360-6369
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6360

Full Size Figure Download Figure

Figure 5 Pharmacokinetics of osimertinib in patients undergoing hemodialysis and those with normal renal function. A: Plasma concentrations of osimertinib were similar among pre-HD, post-HD, and non-HD days; B: The AUC_0–24 of osimertinib were similar among pre-HD, post-HD, and non-HD days. AUC_0-24: Area under the curve of the plasma concentration from 0 to 24 h; HD: Hemodialysis; NRF: Normal renal function.

Citation: Lan CC, Hsieh PC, Huang CY, Yang MC, Su WL, Wu CW, Wu YK. Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis. World J Clin Cases 2022; 10(19): 6360-6369
URL: https://www.wjgnet.com/2307-8960/full/v10/i19/6360.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i19.6360